US 12,291,561 B2
Antigen binding receptors specific for mutated Fc domains
Kay-Gunnar Stubenrauch, Penzberg (DE); Ekkehard Moessner, Schlieren (CH); Christian Klein, Schlieren (CH); and Diana Darowski, Schlieren (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on May 4, 2023, as Appl. No. 18/312,339.
Application 18/312,339 is a division of application No. 16/576,546, filed on Sep. 19, 2019, granted, now 11,679,127.
Application 16/576,546 is a continuation of application No. PCT/EP2018/057566, filed on Mar. 26, 2018.
Claims priority of application No. 17163090 (EP), filed on Mar. 27, 2017.
Prior Publication US 2023/0390338 A1, Dec. 7, 2023
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/70517 (2013.01) [A61K 39/4611 (2023.05); A61K 39/464424 (2023.05); A61K 39/464482 (2023.05); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/71 (2013.01); C07K 16/283 (2013.01); C07K 16/2887 (2013.01); C07K 16/3007 (2013.01); C07K 16/40 (2013.01); A61K 38/00 (2013.01); A61K 2239/48 (2023.05); A61K 2239/50 (2023.05); C07K 2317/32 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01)] 28 Claims
 
1. A transduced T cell capable of expressing an antigen binding receptor comprising an anchoring transmembrane domain and an extracellular domain comprising an antigen binding moiety, wherein the antigen binding moiety is capable of specific binding to a mutated fragment crystallizable (Fc) domain but not capable of specific binding to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises at least one amino acid substitution compared to the non-mutated parent Fc domain, wherein the mutated Fc domain comprises the amino acid mutation P329G according to EU numbering, wherein the antigen binding moiety is capable of specific binding to the mutated Fc domain comprising the P329G mutation but not capable of specific binding to the non-mutated parent Fc domain, and wherein the antigen binding moiety comprises:
(A)
(i) a heavy chain variable region (VH) comprising:
(a) the heavy chain complementarity-determining region (CDR H) 1 amino acid sequence RYWMN (SEQ ID NO:1);
(b) the CDR H2 amino acid sequence EITPDSSTINYTPSLKD (SEQ ID NO:2); and
(c) the CDR H3 amino acid sequence PYDYGAWFAS (SEQ ID NO:3); and
(ii) a light chain variable region (VL) comprising:
(d) the light chain complementary-determining region (CDR L) 1 amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO:4);
(e) the CDR L2 amino acid sequence GTNKRAP (SEQ ID NO:5); and
(f) the CDR L3 amino acid sequence ALWYSNHWV (SEQ ID NO:6); or
(B)
(i) a VH comprising the amino acid sequence of SEQ ID NO:8; and
(ii) a VL comprising the amino acid sequence of SEQ ID NO:9.